Published in J Clin Invest on February 01, 2005
Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity. J Immunol (2009) 1.03
Smallpox inhibitor of complement enzymes (SPICE): regulation of complement activation on cells and mechanism of its cellular attachment. J Immunol (2008) 0.92
Toward orthopoxvirus countermeasures: a novel heteromorphic nucleoside of unusual structure. J Med Chem (2006) 0.87
The DNA helicase-primase complex as a target for herpes viral infection. Expert Opin Ther Targets (2013) 0.82
Host-based Prophylaxis Successfully Targets Liver Stage Malaria Parasites. Mol Ther (2015) 0.82
Variola virus F1L is a Bcl-2-like protein that unlike its vaccinia virus counterpart inhibits apoptosis independent of Bim. Cell Death Dis (2015) 0.78
Gene silencing in the therapy of influenza and other respiratory diseases: Targeting to RNase P by use of External Guide Sequences (EGS). Biologics (2007) 0.75
Synthesis and antiviral activities of new acyclic and "double-headed" nucleoside analogues. Bioorg Chem (2006) 0.75
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
SRC mediates a switch from microtubule- to actin-based motility of vaccinia virus. Science (2004) 2.44
Bioterrorism: a clear and present danger. Nat Med (2001) 2.43
Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol (2004) 2.21
Deletion of the vaccinia virus growth factor gene reduces virus virulence. J Virol (1988) 2.10
Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology (2003) 2.07
Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med (2000) 1.99
Discovery of antivirals against smallpox. Proc Natl Acad Sci U S A (2004) 1.76
Smallpox: anything to declare? Nat Rev Immunol (2002) 1.53
Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J Clin Invest (2005) 1.50
Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network. EMBO J (1998) 1.49
The exit of vaccinia virus from infected cells. Virus Res (2004) 1.46
Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest (2002) 1.26
Biochemical and functional analysis of smallpox growth factor (SPGF) and anti-SPGF monoclonal antibodies. J Biol Chem (2004) 1.11
Epidermal growth factor receptor tyrosine kinase inhibitors. Curr Opin Pharmacol (2002) 1.11
The brightening future of HIV therapeutics. Nat Immunol (2004) 0.98
Small molecule inhibitors of the class 1 receptor tyrosine kinase family. Curr Top Med Chem (2002) 0.96
Transforming growth factor alpha, Shope fibroma growth factor, and vaccinia growth factor can replace myxoma growth factor in the induction of myxomatosis in rabbits. Virology (1993) 0.88
An overview on the use of a viral pathogen as a bioterrorism agent: why smallpox? Antiviral Res (2003) 0.82
Efficacy of cidofovir in the treatment of recalcitrant molluscum contagiosum in an AIDS patient. Acta Derm Venereol (2001) 0.81
Virology. Src launches vaccinia. Science (2004) 0.79